Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
- PMID: 23873022
- DOI: 10.1038/onc.2013.285
Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
Abstract
Human epidermal growth factor receptor 2 (HER2)-directed treatment using trastuzumab has shown clinical benefit in HER2-positive gastric cancer. Clinical trials using lapatinib in HER2-positive gastric cancer are also currently underway. As with other molecularly targeted agents, the emergence of acquired resistance to HER2-directed treatment is an imminent therapeutic problem for HER2-positive gastric cancer. In order to investigate the mechanisms of acquired resistance to HER2-directed treatment in gastric cancer, we generated lapatinib-resistant gastric cancer cell lines (SNU216 LR) in vitro by chronic exposure of a HER2-positive gastric cancer cell line (SNU216) to lapatinib. The resultant SNU216 LR cells were also resistant to gefitinib, cetuximab, trastuzumab, afatinib and dacomitinib. Interestingly, SNU216 LR cells displayed an epithelial-mesenchymal transition (EMT) phenotype and maintained the activation of MET, HER3, Stat3, Akt and mitogen-activated protein kinase signaling in the presence of lapatinib. Using gene expression arrays, we identified the upregulation of a variety of EMT-related genes and extracellular matrix molecules, such as Testican-1, in SNU216 LR cells. We showed that the inhibition of Testican-1 by small interfering RNA decreased Testican-1-induced, MET-dependent, downstream signaling, and restored sensitivity to lapatinib in these cells. Furthermore, treatment with XAV939 selectively inhibited β-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest. Taken together, these data support the potential role of EMT in acquired resistance to HER2-directed treatment in HER2-positive gastric cancer, and provide insights into strategies for preventing and/or overcoming this resistance in patients.
Similar articles
-
FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.Cancer Res Treat. 2018 Jan;50(1):239-254. doi: 10.4143/crt.2016.580. Epub 2017 Mar 24. Cancer Res Treat. 2018. PMID: 28343375 Free PMC article.
-
Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.Clin Cancer Res. 2014 Sep 1;20(17):4559-73. doi: 10.1158/1078-0432.CCR-13-3396. Epub 2014 Jun 27. Clin Cancer Res. 2014. PMID: 24973425
-
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11. Mol Cancer Ther. 2012. PMID: 22238368 Free PMC article.
-
Advanced HER2-positive gastric cancer: current and future targeted therapies.Crit Rev Oncol Hematol. 2013 Mar;85(3):350-62. doi: 10.1016/j.critrevonc.2012.08.008. Epub 2012 Sep 26. Crit Rev Oncol Hematol. 2013. PMID: 23021388 Review.
-
HER2 expression and PI3K-Akt pathway alterations in gastric cancer.Digestion. 2014;89(1):12-7. doi: 10.1159/000356201. Epub 2014 Jan 20. Digestion. 2014. PMID: 24458107 Review.
Cited by
-
Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis.J Exp Clin Cancer Res. 2019 Jun 10;38(1):246. doi: 10.1186/s13046-019-1247-3. J Exp Clin Cancer Res. 2019. PMID: 31182131 Free PMC article.
-
Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System.Materials (Basel). 2015 Feb 5;8(2):519-534. doi: 10.3390/ma8020519. Materials (Basel). 2015. PMID: 28787954 Free PMC article.
-
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Oncotarget. 2015 Oct 20;6(32):32317-38. doi: 10.18632/oncotarget.6094. Oncotarget. 2015. PMID: 26474458 Free PMC article.
-
Proteoglycans and their functions in esophageal squamous cell carcinoma.World J Clin Oncol. 2021 Jul 24;12(7):507-521. doi: 10.5306/wjco.v12.i7.507. World J Clin Oncol. 2021. PMID: 34367925 Free PMC article. Review.
-
Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression.Br J Cancer. 2015 Oct 20;113(8):1186-96. doi: 10.1038/bjc.2015.273. Epub 2015 Oct 8. Br J Cancer. 2015. PMID: 26448177 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous